Additional genetic mutations in MPNs: impact on prognosis
An important study of genetic mutations in MPNs and their impact on prognosis has just been released in ‘Leukaemia’, titled “Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase.”
The authors state “By conducting a thorough genetic analysis, we’ve developed a model that relies on 12 genetic markers to accurately stratify MPN patients. The model can be simplified into a decision tree for routine use.”
“Our data suggest to perform a broader genetic screening at diagnosis and also at clinical progression, as driver mutations may change and the MPN-driver mutations present at diagnosis may disappear.”
Their conclusion is “Consequently, expanding genetic analysis beyond JAK2, CALR, and MPL at diagnosis is crucial for accurate MPN classification, early high-risk patient identification, and timely intervention.”
This important study can be freely accessed HERE.
